Biofrontera (NASDAQ:BFRI – Get Free Report)‘s stock had its “buy” rating reiterated by Benchmark in a report issued on Friday, Benzinga reports. They presently have a $7.00 price target on the stock. Benchmark’s target price suggests a potential upside of 464.47% from the stock’s current price.
Biofrontera Price Performance
Biofrontera stock traded up $0.08 during mid-day trading on Friday, hitting $1.24. 19,314 shares of the company’s stock traded hands, compared to its average volume of 360,003. Biofrontera has a fifty-two week low of $0.61 and a fifty-two week high of $9.70. The stock has a market cap of $6.31 million, a price-to-earnings ratio of -0.09 and a beta of 0.46. The firm has a 50 day simple moving average of $1.04 and a two-hundred day simple moving average of $1.21.
Biofrontera (NASDAQ:BFRI – Get Free Report) last posted its earnings results on Wednesday, May 15th. The company reported ($1.85) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.63) by ($0.22). Biofrontera had a negative return on equity of 1,390.99% and a negative net margin of 69.44%. The firm had revenue of $7.91 million for the quarter, compared to analyst estimates of $11.52 million. On average, research analysts anticipate that Biofrontera will post -3.21 earnings per share for the current fiscal year.
Hedge Funds Weigh In On Biofrontera
About Biofrontera
Biofrontera Inc, a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection.
See Also
- Five stocks we like better than Biofrontera
- How to Calculate Retirement Income: MarketBeat’s Calculator
- Lockheed Martin’s Sky-High Surge: Buy Now or Wait for a Landing?
- What is a Death Cross in Stocks?
- Deere Rebounds on Earnings Beat, But Uphill Battle Remains
- Consumer Discretionary Stocks Explained
- Mutual Funds vs Hedge Funds: What’s the Difference?
Receive News & Ratings for Biofrontera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biofrontera and related companies with MarketBeat.com's FREE daily email newsletter.